ArticleVaccines2022
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.Human vaccines & immunotherapeutics · 2026Trial
- mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model.Scientific reports · 2026Article
- Article
- Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.The Journal of clinical investigation · 2026Article
- Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma.Cancer immunology, immunotherapy : CII · 2025Article
- Pre-clinical evaluation of mRNA-lipid nanoparticles' potency and toxicity: current practices and future directions.In vitro models · 2025Review
- Review
- Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.Virology journal · 2025Review
- mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice.Molecular therapy. Nucleic acids · 2024Article
- Review
- Rational design of an artificial tethered enzyme for non-templated post-transcriptional mRNA polyadenylation by the second generation of the C3P3 system.Scientific reports · 2024Article
- mRNA-Based Vaccines Are Highly Immunogenic and Confer Protection in the Gnotobiotic Pig Model of Human Rotavirus Diarrhea.Vaccines · 2024Article
- Messenger RNA Therapy for Female Reproductive Health.Molecular pharmaceutics · 2024Review
- mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents.NPJ vaccines · 2023Article
- Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.Nature communications · 2023Article
- The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.Journal of pharmaceutical sciences · 2023Review
- From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.Vaccines · 2023Article
- Pre-clinical models to define correlates of protection for SARS-CoV-2.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by antibodies raised against ancestral SARS-CoV-2 are circulating, highlighting the need to adapt vaccination strategies. Here, we compare the immunogenicity of a first-generation mRNA vaccine candidate, CVnCoV, with a second-generation mRNA vaccine candidate, CV2CoV, in rats. Higher levels of spike (S) protein expression were observed in cell culture with the CV2CoV mRNA than with the CVnCoV mRNA. Vaccination with CV2CoV also induced higher titres of virus neutralising antibodies with accelerated kinetics in rats compared with CVnCoV. Significant cross-neutralisation of the SARS-CoV-2 variants, Alpha (B.1.1.7), Beta (B.1.351), and the 'mink' variant (B1.1.298) that were circulating at the time in early 2021 were also demonstrated. In addition, CV2CoV induced higher levels of antibodies at lower doses than CVnCoV, suggesting that dose-sparing could be possible with the next-generation SARS-CoV-2 vaccine, which could improve worldwide vaccine supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.